Drug Approval | May 01, 2026
Dr Reddy’s becomes first to secure Health Canada nod for generic Semaglutide injection
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Market authorization for generic GLP-1 therapy strengthens company’s diabetes portfolio in Canada
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
The deal, backed by healthcare investor ARCHIMED, signals a major push to accelerate connected, patient-centered cardiac care worldwide
With the convergence of AI, robotics, and neuroscience, Motorica is advancing toward more intuitive, intent-driven prosthetic systems
SPARC enters definitive agreement to monetise rare paediatric disease PRV, unlocking capital for R&D and strategic growth
The partnership integrates BD’s ZebraSci, a device-agnostic testing platform, with Suttons Creek’s expertise in combination product development and systems integration
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The Puducherry facility, dedicated to Ibuprofen and its derivatives, is equipped with advanced infrastructure to serve both domestic and international markets
Patalganga plant received zero observation from USFDA earlier
Patients receiving ELREXFIO largely remained free from disease progression during the interim analysis
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
